Cdc42 GTPase and leukemia stem cells have emerged as potential anti-cancer therapeutic targets by recent studies. The proposed work will pursue genetic and pharmacologic targeting of Cdc42 to benefit leukemia therapy by introducing a novel concept that targeting Cdc42 in leukemia stem cells could result in their mobilization from the niche and this could serve as a new means in combinatory therapy. The studies will translate the mechanistic information obtained from the decades-long biochemical, cell biological, and genetic studies of Cdc42 and leukemia into future therapy.
Showing the most recent 10 out of 16 publications